ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

United States Cancer Immunotherapy Market Analysis, Trend & Forecast 2017-2021 – Medgadget (blog)

Continue reading

2017-04-21 Michael Zand NEWS

United States Cancer Immunotherapy Market Analysis, Trend & Forecast 2017-2021 – Medgadget (blog)

United States Cancer Immunotherapy Market Analysis, Trend & Forecast 2017-2021
Medgadget (blog)
“United States Cancer Immunotherapy Market Research Report Forecast 2017-2021” Purchase This Report by calling ResearchnReports.com at +1-888-631-6977. This market research report delves deep into the Cancer Immunotherapy market. It highlights …

and more »

Continue reading

2017-04-21 Michael Zand NEWS

‘Thymus in a Dish’ Generates T-cells – MedPage Today

United States Cancer Immunotherapy Market Analysis, Trend & Forecast 2017-2021
Medgadget (blog)
“United States Cancer Immunotherapy Market Research Report Forecast 2017-2021” Purchase This Report by calling ResearchnReports.com at +1-888-631-6977. This market research report delves deep into the Cancer Immunotherapy market. It highlights …

and more »

Continue reading

2017-04-21 Michael Zand NEWS

Cancer Immunotherapy Market Analysis, Growth, Shares, Size, Trends, Types and Applications with Forecast to 2021 – Medgadget (blog)

Cancer Immunotherapy Market Analysis, Growth, Shares, Size, Trends, Types and Applications with Forecast to 2021Medgadget (blog)Cancer Immunotherapy Market report delivers a basic overview of the industry including Key Players, Regional Segment Analysi… Continue reading

2017-04-21 Michael Zand NEWS

Biotech firm pulls pioneering gene therapy due to no demand – Channel NewsAsia

‘Thymus in a Dish’ Generates T–cells
MedPage Today
The artificial thymus or “thymus in a dish” system is a technically simple, reproducible in vitro model that closely recapitulates human thymopoiesis and generates mature, naive antigen-specific T-cells closely resembling T-cells from the thymus and …

Continue reading

2017-04-21 Michael Zand NEWS

Sensitive CRISPR diagnostics using RNA targeting CRISPR … – PLoS Blogs (blog)

PLoS Blogs (blog)Sensitive CRISPR diagnostics using RNA targeting CRISPR …PLoS Blogs (blog)I was recently involved in a collaboration between the Zhang and Collins labs at MIT to use the RNA-targeting CRISPR protein Cas13a/C2c2 to detect either&nbsp… Continue reading

2017-04-21 Michael Zand NEWS

Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL – OncLive

OncLiveFindings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALLOncLiveLow disease burden prior to treatment with CD19-specific chimeric antigen receptor (CAR) T-cell therapy appears to be a positive prognostic factor for long-term s… Continue reading

2017-04-21 Michael Zand NEWS

CRISPR genome editing and immunotherapy – the early adopter – Cancer Research UK (blog)

Biotech firm pulls pioneering gene therapy due to no demand
Channel NewsAsia
LONDON: The biotech company behind the Western world’s first gene therapy and the most expensive prescription medicine in history is giving up on the product because of lack of demand. Only one patient has been treated commercially since the drug was …

Continue reading

2017-04-21 Michael Zand NEWS
  • 1
  • …
  • 1,815
  • 1,816
  • 1,817
  • 1,818
  • 1,819
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Cancer Research UK (blog)

CRISPR genome editing and immunotherapy – the early adopter
Cancer Research UK (blog)
But among that speculation, one area of medicine has been quick to pick up the technology and is now leading the way in early clinical trials. In this second post in our series taking a closer look at CRISPR, we explore its potential for new …

and more »